drugset / Trial / NCT07502716

Compassionate Use of Ubamatamab

NCT07502716

Expanded access Available Regeneron Pharmaceuticals

Summary

Provide Compassionate Use of Ubamatamab

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Background Ubamatamab Monoclonal antibody